AlphaFold predicted structure
IFNL3 · Q8IZI9

Mean pLDDT
84.8/ 100
Confident
196 residues
Confidence breakdown
- Very high(≥ 90)71%
- Confident(70–90)7%
- Low(50–70)10%
- Very low(< 50)12%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
interferon lambda 3
Annotations refreshed 1 month ago.
Moderate Evidence (Amber)
COVID-19 research
Unknownhepatocellular carcinoma
liver cancer
intrahepatic bile duct cancer
chronic hepatitis C virus infection
neoplasm
systemic lupus erythematosus
liver neoplasm
hepatitis C virus infection
tropical spastic paraparesis
metabolic syndrome
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Interferon lambda-3
Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression
Curated MONDO disease pages that list IFNL3 among their top associated genes.
IFNL3 · Q8IZI9

Mean pLDDT
84.8/ 100
Confident
196 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0